These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1194 related articles for article (PubMed ID: 31862149)
1. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Heerspink HJL; Karasik A; Thuresson M; Melzer-Cohen C; Chodick G; Khunti K; Wilding JPH; Garcia Rodriguez LA; Cea-Soriano L; Kohsaka S; Nicolucci A; Lucisano G; Lin FJ; Wang CY; Wittbrodt E; Fenici P; Kosiborod M Lancet Diabetes Endocrinol; 2020 Jan; 8(1):27-35. PubMed ID: 31862149 [TBL] [Abstract][Full Text] [Related]
2. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064 [TBL] [Abstract][Full Text] [Related]
3. Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database. Nagasu H; Yano Y; Kanegae H; Heerspink HJL; Nangaku M; Hirakawa Y; Sugawara Y; Nakagawa N; Tani Y; Wada J; Sugiyama H; Tsuruya K; Nakano T; Maruyama S; Wada T; Yamagata K; Narita I; Tamura K; Yanagita M; Terada Y; Shigematsu T; Sofue T; Ito T; Okada H; Nakashima N; Kataoka H; Ohe K; Okada M; Itano S; Nishiyama A; Kanda E; Ueki K; Kashihara N Diabetes Care; 2021 Nov; 44(11):2542-2551. PubMed ID: 34593566 [TBL] [Abstract][Full Text] [Related]
4. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Mosenzon O; Wiviott SD; Cahn A; Rozenberg A; Yanuv I; Goodrich EL; Murphy SA; Heerspink HJL; Zelniker TA; Dwyer JP; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Kato ET; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS; Raz I Lancet Diabetes Endocrinol; 2019 Aug; 7(8):606-617. PubMed ID: 31196815 [TBL] [Abstract][Full Text] [Related]
5. Kidney outcomes of SGLT2 inhibitors among older patients with diabetic kidney disease in real-world clinical practice: the Japan Chronic Kidney Disease Database Ex. Kitaoka K; Yano Y; Nagasu H; Kanegae H; Chishima N; Akiyama H; Tamura K; Kashihara N BMJ Open Diabetes Res Care; 2024 May; 12(3):. PubMed ID: 38816204 [TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. Kosiborod M; Lam CSP; Kohsaka S; Kim DJ; Karasik A; Shaw J; Tangri N; Goh SY; Thuresson M; Chen H; Surmont F; Hammar N; Fenici P; J Am Coll Cardiol; 2018 Jun; 71(23):2628-2639. PubMed ID: 29540325 [TBL] [Abstract][Full Text] [Related]
7. Real-world effectiveness of sodium-glucose cotransporter-2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria. Nakhleh A; Abdul-Ghani M; Gazit S; Gross A; Livnat I; Greenbloom M; Yarden A; Khazim K; Shehadeh N; Melzer Cohen C Diabetes Obes Metab; 2024 Aug; 26(8):3058-3067. PubMed ID: 38680053 [TBL] [Abstract][Full Text] [Related]
9. Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease. Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K Diabetes Obes Metab; 2022 Nov; 24(11):2138-2147. PubMed ID: 35676798 [TBL] [Abstract][Full Text] [Related]
10. Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. Kohsaka S; Lam CSP; Kim DJ; Cavender MA; Norhammar A; Jørgensen ME; Birkeland KI; Holl RW; Franch-Nadal J; Tangri N; Shaw JE; Ilomäki J; Karasik A; Goh SY; Chiang CE; Thuresson M; Chen H; Wittbrodt E; Bodegård J; Surmont F; Fenici P; Kosiborod M; Lancet Diabetes Endocrinol; 2020 Jul; 8(7):606-615. PubMed ID: 32559476 [TBL] [Abstract][Full Text] [Related]
11. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267 [TBL] [Abstract][Full Text] [Related]
12. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. EMPA-KIDNEY Collaborative Group Lancet Diabetes Endocrinol; 2024 Jan; 12(1):39-50. PubMed ID: 38061371 [TBL] [Abstract][Full Text] [Related]
13. Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study. Rampersad C; Kraut E; Whitlock RH; Komenda P; Woo V; Rigatto C; Tangri N Am J Kidney Dis; 2020 Oct; 76(4):471-479.e1. PubMed ID: 32464161 [TBL] [Abstract][Full Text] [Related]
14. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Heerspink HJL; Jongs N; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Greene T; Lancet Diabetes Endocrinol; 2021 Nov; 9(11):743-754. PubMed ID: 34619108 [TBL] [Abstract][Full Text] [Related]
15. Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL. Clegg LE; Heerspink HJL; Penland RC; Tang W; Boulton DW; Bachina S; Fox RD; Fenici P; Thuresson M; Mentz RJ; Hernandez AF; Holman RR Diabetes Care; 2019 Feb; 42(2):318-326. PubMed ID: 30523029 [TBL] [Abstract][Full Text] [Related]
16. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Neuen BL; Young T; Heerspink HJL; Neal B; Perkovic V; Billot L; Mahaffey KW; Charytan DM; Wheeler DC; Arnott C; Bompoint S; Levin A; Jardine MJ Lancet Diabetes Endocrinol; 2019 Nov; 7(11):845-854. PubMed ID: 31495651 [TBL] [Abstract][Full Text] [Related]
17. Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study. Kosiborod M; Birkeland KI; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Jørgensen ME; Wittbrodt ET; Thuresson M; Bodegård J; Hammar N; Fenici P; Diabetes Obes Metab; 2018 Aug; 20(8):1983-1987. PubMed ID: 29569378 [TBL] [Abstract][Full Text] [Related]
18. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. ; Lancet; 2022 Nov; 400(10365):1788-1801. PubMed ID: 36351458 [TBL] [Abstract][Full Text] [Related]
19. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Kosiborod M; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Birkeland KI; Jørgensen ME; Thuresson M; Arya N; Bodegård J; Hammar N; Fenici P; Circulation; 2017 Jul; 136(3):249-259. PubMed ID: 28522450 [TBL] [Abstract][Full Text] [Related]
20. Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database. Zhou FL; Watada H; Tajima Y; Berthelot M; Kang D; Esnault C; Shuto Y; Maegawa H; Koya D Diabetes Obes Metab; 2019 Aug; 21(8):1925-1934. PubMed ID: 31050099 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]